In-silico functional analyses were conducted on the gene signature used for subtype prediction. The 24 predicted subtypes showed distinct but statistically insignificant overall survival distribution
Introduction

35
Colorectal cancer (CRC) is the third-leading cancer type for the estimated new cancer cases and 36 deaths in 2010 US population with 142,570 (9%) cases and 51,370 (9%) deaths respectively [1] . In
37
Saudi population it is the most frequent type of cancer in male (13.9%) and third-frequent in female
38
(10.2%) [Saudi Cancer Registry, 2013] 
58
In the present study we used a genome-wide mRNA expression analysis of 48 matched normal
59
and tumor sample pairs from Saudi CRC patients using Affymetrix exon arrays [20] . We applied one 
Materials and Methods
67
Ethical approval and sample collection
68
The study was approved ethically by the Institutional Review Board (IRB) of King Abdullah
69
International Medical Research Center after a review process. The CRC patients were recruited for 70 the study and the tissue samples were collected after the informed consent signed by the patients.
71
The samples were collected either by biopsies or surgical resections from the forty-eight 72 patients upon their first presentation in the clinic for CRC diagnosis. 
Exon Microarray
86
The tumor and normal tissue specimen weighed between 10-30 mg. The tissue samples were stored
87
in RNAlater (Ambion) at 4o C for 24 hrs followed by freezing and further storage at -20 o C. RNA
88
was extracted from these tissues using Macherey Nagel RNA extraction kit (Germany) in a single
89
preparation. The quality and quantity of the extracted RNA was checked using Nanodrop (Thermo
90
Fischer Scientific, USA).
91
Genome-wide gene expression profile of tumor and matched normal samples were obtained using
92
GeneChipTM Human Exon 1.0 ST Arrays from Affymetrix following the manufacturer's protocol.
93
This array is also used to study alternative splicing in human genome on a genome-wide scale. In the 
122
approach has been implemented in the R package "citccmst" [14] . There are various steps underlying
123
the prediction algorithm as mentioned in the manual of "citccmst" in R. Those are briefly described
124
here for the sake of clarity.
125
1. Mapping the genes from our CRC tumor expression dataset to the 57 discriminating 126 genes/probes used in centroid calculation in "citccmst" from discovery dataset [14] .
127
2. Averaging expression measures per gene symbol both in our CRC dataset and in the 128 citccmst discovery dataset. In any case, our CRC data and the citccmst discovery set data are 129 reduced to discrimating probes/genes measured in both datasets.
130
3. Recomputing the centroids of each 6 subtypes using citccmst discovery dataset from step 2. 
137
Thus, in the present study the "citccmst" (http://cit.ligue-cancer.net) R package was used to predict 138 the subtypes of colorectal cancer samples.
139
Survival analysis
140
The patient's overall survival probabilities were analyzed using Kaplan-Meier estimator.
141
Kaplan-Meier estimator is a non-parametric statistical test that estimates the survival function from 142 patient's survival data. The overall survival is defined as the time from the diagnosis or the start of 143 treatment of CRC until the patient remains alive. The overall survival probabilities were plotted for 144 the six predicted subtypes. The survival distribution of each molecular subtype manifests the 145 biological significance of the subtype. The survival distributions were compared using log-rank test.
146
The R software package "survival" and "survminer" were used for the Kaplan-Meier survival 147 analysis and SAS procedure "Phreg" was used for cox-regression.
Differential gene expression analysis
149
The genes which are significantly differentially expressed in tumor samples compared to the 
165
The overall analyses strategy adopted in the current study has been summarized as an illustration in 
172
We tested the CRC samples for any anomalies or outliers in the exon microarray data generation.
173
The proximity based models such as clustering method marked two samples as potential outliers.
174
Moreover, principal component analysis and heatmap also highlighted the same two samples as 
Prognostic value of the predicted subtypes
198
The patient's survival data was analyzed to see the overall survival distributions after grouping the 199 patients into predicted subtypes (Figure 3 ). The differences between survival distributions among 200 subtypes were compared using log-rank test with an endpoint of four year overall survival. The
201
survival probabilities among all six subtypes differ greatly to each other however not statistically 202 significant (P-value: 0.069). This might be due to the insufficient number of subjects in each subtype.
203
The patients with C4 and C6 subtypes showed poor outcome in overall survival (median survival 
245
We carried out network analysis of the 57 genes used for classification ( Figure 5B ). Eleven of these 246 genes were part of the network which has top score of nineteen. Only three out of these 11 genes
247
were found to be differentially expressed in our CRC tumor samples compared to the matched 
Biomarker analysis of gene signature
257
We carried out biomarker analysis of the 57 gene signature to assess the potential of these genes as 258 biomarkers for diagnosis, efficacy, disease progression and prognosis. Six of these genes were
259
found to be candidate biomarkers that could be detected in Human blood, Plasma/serum, Urine,
260
blood platelets, cytotoxic and effector T cells and large intestine. Out of these six genes five (83 %)
261
were found to be differentially expressed in our CRC tumor samples compared to the matched 262 normal tissue samples. CA2 and HPSE were the genes which were targets for many drugs (Table 2) . 
263
277
Though the number of samples used by 'citccmst' for classification (n=443) was much higher than 278 our dataset (n=48), this particular classification scheme was able to capture all six subtypes in our 279 sample. This was expected given that the least subtype group (C6) in the citccmst' dataset represents 280 about 10.2% which suggests that in our dataset one might expect to observe 4.8 subjects on average.
281
Our results suggests that the distribution of the subtypes across our dataset and citccmst' CRC 282 tumor samples are significantly different (Chi-square test, p=0.0091). One explanation of these 283 findings is that the patterns of the genes involved in the subtyping differ across populations..
284
Another explanation might be that the distribution of the subtypes might reflects the clinical 285 heterogeneity between our population and the original citccmst' dataset. This is apparent by the fact 286 that patients in our dataset are younger, and tend to have less of stage IV compared to CITCCMST.
287
The latter is more plausible given the fact that the different subtypes reflects the underlying 288 moleculrate state of the cancer as described by Marisital et. al[14] . This is an important feature of a 
294
The prognostic value of the identified subtypes is evident by the survival pattern of the patients 295 belonging to specific subgroups. Though our dataset is limited by the number of patients in each 296 subgroup, the pattern of survival probability is similar with subgroups C4 and C6 exhibiting the 297 worst outcome whereas C2 and C3 show the best prognosis. 
309
Further, we analyzed the biological relevance of the 57 genes signature in terms of the associated 310 disease and networks. As expected, the most significantly associated disease was cancer followed by 311 gastrointestinal disease. However, only 4 genes matched to the genes associated with colorectal 312 adenoma. Of these CA1 gene was significantly down-regulated in our patient cohort which confirms 313 previous results in TCGA data set [28] . CA1 has also been used in the gene classifier that is 314 associated with cellular phenotype [18] and using single cell approach [29] . Usually classification 315 gene signatures with functionally relevant genes are helpful in explaining the biology of the 316 colorectal cancer subtypes. As we have reported earlier 28/30 genes used for classification were 317 associated with colorectal cancer. However these genes were used to classify tumor and normal 318 samples [30] . We further analyzed the differential expression of the 57 genes between our normal 319 and matched cases and found some of them to be significantly differentially expressed. We 320 constructed network of genes in the classification signature based on their association. The most 321 statistically significant network had 11 of the 57 genes. Of these IGFBP5, IL1B and NKD1 were found 322 to be up regulated while CA1 and TSPAN1 were down regulated in our patient cohort. Out of these 323 11 genes, 8 genes were not differentially expressed in our CRC tumor samples. This might reflect the 324 underlying difference in gene expression program in Saudi CRC patients. In the biomarker analysis 325 using IPA the six (out of 57) genes are found to be as potential biomarkers. And to our surprise 5 of 326 these six genes were found to be differentially expressed in our CRC tumor samples. It proves the 327 usability of these five genes as potential biomarkers in Saudi CRC patients. Moreover, each of the 17 328 genes (22 -5) which were shown to be differentially expressed but not reported as biomarkers in the 329 IPA analysis in Saudi CRC tumor samples is a target for further investigation to be used as a 330 potential biomarker in Saudi population.
331
We also checked the overlap of statistically significant differentially expressed genes across the 332 predicted subtypes. There was variable number of genes in each subtype that were differentially 333 expressed with respect to the rest of the subtypes. Most of the genes in each subtype were common 334 with one or more subtypes. But some of the genes are unique in each subgroup except for C3. These 335 unique genes provide an opportunity for suggesting subtype specific targets which may have utility 336 as biomarkers.
337
Limitations
338
One obvious limitation of our study is the small sample size and therefore larger cohort of
339
Saudi colorectal cancer patients might be needed to confirm our observations. Our analysis did not
